Phase 2 N=61 Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
Breast Cancer Female
Primary: Measure Ki67 Index in Highly Hormone-dependent Breast Cancers vs. Those That Are Not — 7; 6; 40 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=36 Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
Breast Cancer · Stage II Breast Cancer · Stage III Breast Cancer
Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants
Phase 3 N=380 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Phase 2 N=37 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Phase 3 N=4,884 Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
Breast Cancer
Primary: Disease-free Survival (DFS) — 87.5; 85.8 percentage of patients — p=.31
Phase 2 N=120 Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer
Breast Cancer
Primary: Objective Response Rate (ORR) Determined by Clinical Palpation — 58.9; 53.8 percentage of participants
Phase 3 N=235 Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Post Menopausal Breast Cancer
Primary: Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades — 4; 0; 4; 195 Participants
Phase 3 N=7,576 Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer
Breast Cancer
Primary: Event-free Survival — 88; 89 percentage of participants — p=0.85
Phase 2 N=26 Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Breast Cancer
Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants
Phase 3 N=3,066 Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Estrogen Receptor Positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Carcinoma
Primary: Disease-free Survival — 84.7; 86.6; 89 percentage of participants — p=0.1
Phase 2 N=40 Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
Breast Cancer
Primary: Time to Progression (TTP) in Women With Hormone Responsive Advanced Breast Cancer Treated With Combination of Exemestane and Fulvestrant. — 6.9 months
N/A N=13 Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
Estrogen Receptor-positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Cancer
Primary: Number of Participants With Grade 4 Toxicity
Phase 3 N=740 Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
Breast Cancer
Primary: Disease-free Survival — 64; 71; 70 percentage of participants
Phase 2 N=16 Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Breast Cancer
Primary: Tolerability at One Year of Ovarian Function Suppression (OFS) Using Leuprolide and Letrozole. — 4 participants
Phase 3 N=622 Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Breast Cancer
Primary: Clinical Response (Complete or Partial Response) Rate (Cohort A) — 62.9; 74.8; 69.1 percentage of patients
Phase 3 N=1,384 EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer
Breast Cancer
Primary: Number of Participants With Disease-free Survival (DFS) Event — 127; 170 Participants
Phase 2 N=66 Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer
Breast Neoplasms
Primary: Clinical Benefit Rate (CR Plus PR Plus SD) — 0; 0; 3; 1 participants
Phase 2 N=35 Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
Breast Cancer
Primary: Objective Response Rate (ORR) — 37.5 percentage of participants
Phase 2 N=30 Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer
Breast Cancer Metastatic
Primary: Progression-free Survival (PFS) — 5 months
Phase 3 N=672 Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Advanced Metastatic Breast Cancer
Primary: Progression Free Survival (PFS) by Investigator Assessment — 23.8; 13.0 Months — p=<0.0000001
Phase 3 N=249 Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
Breast Cancer
Primary: Overall Survival — 2.14; 2.00 years
Phase 3 N=4,172 Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Breast Cancer
Primary: Disease Free Survival — NA; NA Months — p=0.3150
Phase 3 N=724 Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Breast Cancer
Primary: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. — 6.93; 2.83 months — p=<0.0001
Phase 2 N=72 Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
Breast Cancer
Primary: Change in Ki-67 Levels From Baseline (Pre) to Day 28 (Post) Biopsy Samples — -1.3632; -1.6237 log-transformed Ki67% — p=0.6202
Phase 2 N=48 Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Breast Cancer
Primary: Median Progression Free Survival (PFS) — 7.2 months
Phase 3 N=263 A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women
Primary: Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4) — -4.63; 0.37 Percent Change
Phase 2 N=42 Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
Invasive Breast Cancer
Primary: Pathologic Complete Response (PCR) Rate — 0 participants
Phase 3 N=298 Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer
Breast Neoplasms
Primary: Time to Progression (TTP) - Expert Evaluation Committee Assessment — 13.8; 11.1 months
Phase 2 N=72 Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Postmenopausal Women · Locally Advanced Metastatic Breast Cancer · Metastatic Breast Cancer
Primary: Percentage of Participants With Overall Response Rate (ORR) — 37.2 Percentage of Participants
Phase 2 N=13 Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer
Breast Cancer
Primary: Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence) — 6; 7…